The Safety and Efficacy of Combination Therapy of Dapagliflozin and Metformin in Patient with Type 2 Diabetes Mellitus: A Review Study  

作　　者：Saif K. Alkhanferi Khadeejah H. Alhuraiz Hussein S. Alyami Sultan L. Alenazi Mohammed F. Aldhaban Naif Alrowedann Yazeed Y. Albedaiwi Nawal Alnazawi Abrar Bokhamseen Fatimah A. Talaqof Saif K. Alkhanferi;Khadeejah H. Alhuraiz;Hussein S. Alyami;Sultan L. Alenazi;Mohammed F. Aldhaban;Naif Alrowedann;Yazeed Y. Albedaiwi;Nawal Alnazawi;Abrar Bokhamseen;Fatimah A. Talaqof(King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia;King Abdullah International Medical Research Center, Riyadh, Saudi Arabia;Imam Abdurrahman Bin Faisal Hospital, National Guard Health Affairs, Dammam, Saudi Arabia;Qassim Primary Health Care Center, National Guard Health Affairs, Qassim, Saudi Arabia)

机构地区：[1]King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia [2]King Abdullah International Medical Research Center, Riyadh, Saudi Arabia [3]Imam Abdurrahman Bin Faisal Hospital, National Guard Health Affairs, Dammam, Saudi Arabia [4]Qassim Primary Health Care Center, National Guard Health Affairs, Qassim, Saudi Arabia

出　　处：《Journal of Diabetes Mellitus》2022年第4期271-283,共13页糖尿病（英文）

摘　　要：Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class that approved by FDA for patient with type 2 DM. Dapagliflozin alone or in combination therapy with metformin provided effective glycemic control and HbA_1c reduction, with minimal hypoglycemia and hypotension adverse effects. Objective: To evaluate the safety and efficacy of the combination therapy of dapagliflozin and metformin in type 2 diabetes mellitus patients. Methods: Research was conducted through MEDLINE and Embase databases in search of randomized controlled studies including dapagliflozin, sodium glucose co-transporter 2, metformin, and efficacy. Results: Forty seven articles were spotted, 3 randomized controlled studies were involved in this review. Dapagliflozin and metformin combination was found beneficial in HbA_1c reduction equal to 20.7% - 31.5% from the baseline compared to patients on metformin alone. 40.6% of patients on combination therapy achieved the ADA recommended reduction in HbA_1c to less than 7%. Moreover fasting plasma glucose level was reduced by 23.4 mg/dl from the baseline in the combination therapy compared to 5.9 mg/dl in metformin group. Body weight reduction was statistically significant (P Conclusion: The combination therapy of dapagliflozin and metformin found to be safe and effective in type 2 diabetes mellitus management with minimal adverse effects.Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new class that approved by FDA for patient with type 2 DM. Dapagliflozin alone or in combination therapy with metformin provided effective glycemic control and HbA_1c reduction, with minimal hypoglycemia and hypotension adverse effects. Objective: To evaluate the safety and efficacy of the combination therapy of dapagliflozin and metformin in type 2 diabetes mellitus patients. Methods: Research was conducted through MEDLINE and Embase databases in search of randomized controlled studies including dapagliflozin, sodium glucose co-transporter 2, metformin, and efficacy. Results: Forty seven articles were spotted, 3 randomized controlled studies were involved in this review. Dapagliflozin and metformin combination was found beneficial in HbA_1c reduction equal to 20.7% - 31.5% from the baseline compared to patients on metformin alone. 40.6% of patients on combination therapy achieved the ADA recommended reduction in HbA_1c to less than 7%. Moreover fasting plasma glucose level was reduced by 23.4 mg/dl from the baseline in the combination therapy compared to 5.9 mg/dl in metformin group. Body weight reduction was statistically significant (P Conclusion: The combination therapy of dapagliflozin and metformin found to be safe and effective in type 2 diabetes mellitus management with minimal adverse effects.

关 键 词：DAPAGLIFLOZIN Sodium Glucose Co-Transporter 2 SGLT2 METFORMIN EFFICACY 

分 类 号：R58[医药卫生—内分泌]